145 related articles for article (PubMed ID: 17083769)
1. Remission in ankylosing spondylitis.
Zochling J; Braun J
Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-88-92. PubMed ID: 17083769
[TBL] [Abstract][Full Text] [Related]
2. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.
Braun J; Davis J; Dougados M; Sieper J; van der Linden S; van der Heijde D;
Ann Rheum Dis; 2006 Mar; 65(3):316-20. PubMed ID: 16096329
[TBL] [Abstract][Full Text] [Related]
3. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials.
Baraliakos X; Koenig AS; Jones H; Szumski A; Collier D; Bananis E
J Rheumatol; 2015 Aug; 42(8):1418-26. PubMed ID: 26077401
[TBL] [Abstract][Full Text] [Related]
6. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
[TBL] [Abstract][Full Text] [Related]
7. Excellent endpoints from step-down bridge combination therapy of 5 immunosuppressants in NSAID-refractory ankylosing spondylitis: 6 year international study in Asia - WHO-ILAR COPCORD stage II treatment of the autoimmune diseases.
Darmawan J; Nasution AR; Chen SL; Haq SA; Zhao D; Zeng Q; Davatchi F
J Rheumatol; 2006 Dec; 33(12):2484-92. PubMed ID: 17143982
[TBL] [Abstract][Full Text] [Related]
8. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
[TBL] [Abstract][Full Text] [Related]
9. Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy.
Prince DS; McGuigan LE; McGirr EE
Int J Rheum Dis; 2014 Feb; 17(2):165-72. PubMed ID: 24576272
[TBL] [Abstract][Full Text] [Related]
10. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial.
Haibel H; Brandt HC; Song IH; Brandt A; Listing J; Rudwaleit M; Sieper J
Ann Rheum Dis; 2007 Mar; 66(3):419-21. PubMed ID: 16901959
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.
Poddubnyy D; Gensler LS
Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):807-18. PubMed ID: 25488786
[TBL] [Abstract][Full Text] [Related]
12. [A short-term efficacy and safety study of infliximab in active ankylosing spondylitis].
Huang F; Zhang LY; Zhang JL; Zhang FC; Liang DF; Deng XH; Guo JH; Zhu J; Zhao W; Li XF; Hou Y
Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):122-6. PubMed ID: 16624120
[TBL] [Abstract][Full Text] [Related]
13. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
Baraliakos X; Brandt J; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2005 Dec; 53(6):856-63. PubMed ID: 16342093
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
[TBL] [Abstract][Full Text] [Related]
15. Ankylosing spondylitis.
Braun J; Sieper J
Lancet; 2007 Apr; 369(9570):1379-1390. PubMed ID: 17448825
[TBL] [Abstract][Full Text] [Related]
16. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
[TBL] [Abstract][Full Text] [Related]
17. The classification and diagnostic criteria of ankylosing spondylitis.
Raychaudhuri SP; Deodhar A
J Autoimmun; 2014; 48-49():128-33. PubMed ID: 24534717
[TBL] [Abstract][Full Text] [Related]
18. How to define remission in ankylosing spondylitis?
Sieper J
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i93-5. PubMed ID: 22460148
[No Abstract] [Full Text] [Related]
19. Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis.
Ren L; Li J; Luo R; Tang R; Zhu S; Wan L
Am J Med Sci; 2013 Dec; 346(6):455-61. PubMed ID: 23715113
[TBL] [Abstract][Full Text] [Related]
20. Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design?
Kiltz U; Baraliakos X; Braun J; van der Heijde D
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S47-50. PubMed ID: 24129137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
